Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence

By afschroeder • June 11, 2025

Sugumar K, Alabd A, Alabd A, Hue JJ, Lyons J, Fields S, Wainberg Z, Zheng L, Coogle B, Kasi A, Grewal N, Kindler HL, Starr J, Sama AR, Winter JM. Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence. Oncotarget. 2025 Jun 10;16:427-442. doi: 10.18632/oncotarget.28739. PMID: 40492845; PMCID: PMC12151408.

Tags: DGSOM Student, exceptional responders, Hematology/Oncology, immunotherapy, microsatellite instability, Pancreatic adenocarcinoma, Publications, survival

Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer

Silverstein J, Smick A, Johnson B, Konecny GE. Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. Future Oncol. 2025[...]

DNA methylation patterns in breast cancer, paired benign tissue from ipsilateral and contralateral breast, and healthy controls

Dennis SR, Tsukioki T, Cottone G, Zhou W, Ganz PA, Sehl ME, Luo Y, Khan SA, Clare S. DNA methylation patterns in breast cancer, paired[...]

Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas

Harrington KJ, Champiat S, Brody JD, Cho BC, Romano E, Golan T, Hyngstrom JR, Strauss J, Oh DY, Popovtzer A, Gomez-Roca C, Perets R, Kim[...]